Navigation Links
Favrille to Host Conference Call and Live Webcast to Discuss Fourth Quarter and Year End 2007 Financial Results on February 19, 2008
Date:2/5/2008

SAN DIEGO, Feb. 5 /PRNewswire-FirstCall/ -- Favrille, Inc. (Nasdaq: FVRL), a biopharmaceutical company developing patient-specific, active immunotherapies for the treatment of cancer, announced today that it will host a conference call and live webcast at 5:00 p.m. Eastern Time on Tuesday, February 19, 2008 to discuss the Company's fourth quarter and year end 2007 financial results. A press release will be issued before the U.S. stock markets open that morning.

A live audio webcast of management's presentation will be available on the Investor Relations section of the Company's web site at http://www.favrille.com. Alternatively, callers may participate in the conference call by dialing (888) 713-4213 or (617) 213-4865, passcode 19388148. To pre-register for this call, please go to https://www.theconferencingservice.com/prereg/key.process?key=P9YHNKNHB. Callers who pre-register will be given a unique PIN to gain immediate access to the call and bypass the live operator. You may pre-register at any time, including up to and after the call start time. A telephone replay of the call will also be available for 48 hours. The telephone replay can be accessed by dialing (888) 286-8010 or (617) 801-6888, passcode 99385491.

About Favrille, Inc.

Favrille, Inc. is a biopharmaceutical company focused on the development and commercialization of targeted immunotherapies for the treatment of cancer and other diseases of the immune system. The Company's lead product candidate, Specifid(TM) (formerly FavId(R)), is based upon unique genetic information extracted from a patient's tumor. Specifid is currently under investigation in a pivotal Phase 3 clinical trial for patients with follicular B-cell non- Hodgkin's lymphoma (NHL) and Phase 2 clinical trials in other B-cell NHL indications. The Company is develo
'/>"/>

SOURCE Favrille, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Favrille to Report New Data on FavId (Now Specifid) at American Society of Hematology Annual Meeting
2. AtriCure to Present at Thomas Weisel Partners 2007 Healthcare Conference
3. Matrixx Initiatives, Inc. to Present at the Roth Capital Partners 2007 New York Conference
4. BD to Present at the Bear Stearns 20th Annual Healthcare Conference
5. GPhAs 2007 Annual Policy Conference Features Top Generic Industry CEOs; FDA, Government Officials; Wall Street Analysts
6. ATS Medical to Present at the 2007 Thomas Weisel Partners Healthcare Conference
7. Omnicell to Present at Thomas Weisel Healthcare Conference 2007
8. AtriCure to Present at Roth Capital Partners 2007 New York Conference
9. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
10. MDS to Present at Thomas Weisel Partners Healthcare Conference
11. Hospira to Present at the Bear Stearns 20th Annual Healthcare Conference on September 11
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/9/2014)... for more than watching World Cup highlights, Brian Williams ... landing in unfortunate positions on railings. A University of ... Online Journal shows that YouTube also allows researchers, ... public on topics of skin cancer and prevention. , ... the future of how we communicate around the world," ...
(Date:7/9/2014)... Infectious Diseases (NIAID), part of the National Institutes ... of CRS3123, an investigational oral antibiotic intended to ... ) infection. CRS3123 (previously known as REP3123) is ... while sparing normal intestinal bacteria. , The Phase ... men and women ages 18 to 45 in ...
(Date:7/9/2014)... A retrospective study conducted by researchers at Tufts ... among adults with intellectual and developmental disabilities, the likelihood ... receiving dental care increased. The findings, published in the ... may help improve interventions designed to address the oral ... researchers reviewed the dental records of 107 patients at ...
(Date:7/9/2014)... older age with kidney and heart disease have raised ... older adults. However, in the first study to look ... of Medicine at the University of Pennsylvania report that ... life expectancy and cardiovascular health as very healthy older ... of the ever increasing organ transplant waitlists, the authors ...
(Date:7/9/2014)... published in the scientific journal Nature Neuroscience ... at Universit Laval, reveals that it is possible to ... rekindling pain so that it can subsequently be erased. ... chronic pain. , The researchers from the Faculty of ... mentale de Qubec (IUSMQ) were inspired by previous work ...
Breaking Medicine News(10 mins):Health News:Study of dermatology on YouTube shows new ways science reaches public 2Health News:NIH launches Phase I clinical trial of novel drug to treat Clostridium difficile infection 2Health News:Adults with special needs see gains, challenges with long term oral care 2Health News:Adults with special needs see gains, challenges with long term oral care 3Health News:Penn study finds living kidney donation does not increase risk of death or heart disease for older 2Health News:Discovery of a new means to erase pain 2
... a challenge for patients in the U.S. health care ... an updated paper released today. Racial and Ethnic ... a policy paper that was originally released in 2003, ... racial and ethnic minority patients and their white counterparts. ...
... bioGUNE and led by Dr. Aitor Hierro, have opened ... of neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS), ... of the National Academy of Sciences of the ... possibility of research in humans to detect this pathology ...
... 2010 The Marilyn B. Gula Mountains of Hope ... a $50,000 donation to the Phoenix-based Translational Genomics Research ... of $300,000. In addition, the Mountains of Hope ... Hospitals (UH) Ireland Cancer Center, bringing the total donated ...
... during surgery for less complicated congenital heart defects ... neurocognitive abilities, such as intelligence, memory, motor skills ... Hospital of Philadelphia, in a study in the ... neuropsychological effects after surgery for acyanotic heart defects. ...
... School of Medicine have discovered that a kind of ... but not found in humans provokes a strong immune ... chronic inflammation is a major issue. This non-human ... drugs, and may be limiting or undermining their therapeutic ...
... , FRIDAY, July 23 (HealthDay News) -- As the nation ... Disabilities Act on Monday, a new survey finds that the ... of life for people with disabilities. Many social and ... disabilities and those without, according to a survey conducted by ...
Cached Medicine News:Health News:Disparities remain a challenge in health care says American College of Physicians 2Health News:New approach which can help to predict neurodegenerative diseases 2Health News:New approach which can help to predict neurodegenerative diseases 3Health News:The Marilyn B. Gula Mountains of Hope Foundation donates additional research funds to TGen 2Health News:Heart bypass for uncomplicated heart surgery does not reduce neurocognitive function in children 2Health News:Non-human sugar in biotech drugs causes inflammation 2Health News:Non-human sugar in biotech drugs causes inflammation 3Health News:Americans With Disabilities Act Reaches 20th Anniversary 2Health News:Americans With Disabilities Act Reaches 20th Anniversary 3Health News:Americans With Disabilities Act Reaches 20th Anniversary 4
(Date:1/15/2014)...  Humberto C. Antunes,  Galderma  worldwide CEO, will receive a ... of Drugs in Dermatology (JDD) at the upcoming ... is January 17-20, 2014, at the Omni Orlando Resort at ChampionsGate ... The ODAC is a distinguished event that delivers a ...
(Date:1/15/2014)... 15, 2014 MultiCell Technologies, Inc. (OTC Bulletin Board: ... patent application concerning composition of matter, biological targets, mechanism ... cell death.  This patent application describes ... RNA molecules (VSRNAs) which interfere with the basic homeostatic ...
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com ... is available in its catalogue: ... Drug Forecast and Market Analysis to 2022 ... PharmaPoint: Atopic Dermatitis - India Drug Forecast ...
Breaking Medicine Technology:Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: